International › Sweden · Last reviewed 2026-05-16
Sweden — Karolinska and SBU
Summary
In spring 2021 the Astrid Lindgren Children's Hospital of Karolinska University Hospital decided to start hormonal treatment of under-18s with gender dysphoria only within an ethically approved clinical study (source). The SBU systematic review of February 2022 found the evidence insufficient to assess the effects of hormone treatment (source). In December 2022 Socialstyrelsen assessed that at group level the risks of puberty blockers and gender-affirming treatment are likely to outweigh the expected benefits, and recommended that treatment be given only in exceptional cases (source).
1. Karolinska University Hospital — policy spring 2021
In spring 2021 the Astrid Lindgren Children's Hospital, part of Karolinska University Hospital, decided to start hormonal treatment of children and adolescents under 18 with gender dysphoria only within a clinical research study approved by the ethical review authority, citing concerns about patient safety, ethics and the state of medical knowledge. While waiting for such a study, an individual assessment could allow treatment in exceptional cases (source). See the extensive summary under /evaluations/karolinska-2021/.1
2. SBU — systematic review (February 2022)
The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) published a systematic review on 22 February 2022 (report 342). It found the evidence insufficient to assess the effects of hormone treatment of children with gender dysphoria; the few long-term studies were small and had many dropouts (source).2 See /evaluations/sbu-2022/.
3. Socialstyrelsen — recommendations December 2022
The Swedish Socialstyrelsen (National Board of Health and Welfare) published updated recommendations in December 2022. It assesses that at group level the risks of puberty blockers and gender-affirming treatment are likely to outweigh the expected benefits, and gives weak negative recommendations: treatment with GnRH analogues and gender-affirming hormones can be given in exceptional cases. For individual decisions it recommends the criteria of the Dutch Protocol (source).3
See also
- Karolinska policy document: Karolinska 2021
- SBU systematic review: SBU 2022
- Comparable national policy changes: Finland, Norway, UK
- Worldwide overview: Status 2025
- International comparison — Sweden alongside other countries in table.
- People register — Karolinska and Socialstyrelsen figures.
- Timeline — policy decisions chronologically.
- FAQ · Glossary.
Footnotes
- Astrid Lindgrens barnsjukhus, Karolinska Universitetssjukhuset. Vanliga frågor och svar angående Socialstyrelsens uppdaterade kunskapsstöd för hormonell behandling vid könsinkongruens och Astrid Lindgrens barnsjukhus riktlinje. 2022.
- SBU. Hormone therapy at gender dysphoria in adolescents. Stockholm: SBU; 2022. Report 342.
- Socialstyrelsen. Vård vid könsdysfori — Kunskapsstöd för vård av barn och ungdomar. Stockholm; December 2022.
Karolinska / Sweden across the network
Other sites in this network also cover this topic:
Karolinska leaves the Dutch Protocol
genderballast.nl
Karolinska stops puberty blockers — May 2021
gendergekte.nl
Karolinska 2021
transgenderidentiteit.nl
Karolinska + Socialstyrelsen (Sweden)
genderrisico.nl